Tongling Jieya Biologic Technology Co., Ltd. (SHE:301108)
China · Delayed Price · Currency is CNY 33.80
-0.06 (-0.18%)
At close: Feb 6, 2026
SHE:301108 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | 52.68 | 19.46 | 115.2 | 140.97 | 220.05 | 179.63 |
Depreciation & Amortization | 46.58 | 46.58 | 39.06 | 34.41 | 30.81 | 16.79 |
Other Amortization | 1.12 | 1.12 | 0.12 | - | - | - |
Loss (Gain) From Sale of Assets | 0.03 | 0.03 | -0.32 | -1.15 | -0.29 | -0.57 |
Asset Writedown & Restructuring Costs | 17.49 | 17.49 | 10.51 | 11.46 | 0.42 | 0.57 |
Loss (Gain) From Sale of Investments | -13.31 | -13.31 | -29.13 | -12.93 | - | - |
Provision & Write-off of Bad Debts | 8.12 | 8.12 | -1.23 | 0.79 | 0.67 | 2.98 |
Other Operating Activities | -124.5 | -2.63 | -4.98 | -6.74 | 5.88 | 7.99 |
Change in Accounts Receivable | 21.05 | 21.05 | -29.87 | 36.39 | -6.34 | -101.08 |
Change in Inventory | -13.39 | -13.39 | -6.33 | 76.74 | -43.14 | -65.72 |
Change in Accounts Payable | -26.87 | -26.87 | -10.84 | -46.66 | -12.36 | 191.62 |
Change in Other Net Operating Assets | 13.69 | 13.69 | -1.68 | 65.52 | -3.26 | -52.4 |
Operating Cash Flow | -13.53 | 75.12 | 83.51 | 299.02 | 200.18 | 187.56 |
Operating Cash Flow Growth | - | -10.05% | -72.07% | 49.38% | 6.73% | 75.50% |
Capital Expenditures | -219.73 | -96.23 | -85.05 | -29.91 | -72.59 | -103.2 |
Sale of Property, Plant & Equipment | 6.69 | 0.62 | 0.38 | 0.35 | 0.12 | - |
Investment in Securities | 374.1 | -211.12 | -311.78 | -570 | - | - |
Other Investing Activities | 66.27 | 36.18 | 4.84 | 2.99 | -5 | 5 |
Investing Cash Flow | 227.32 | -270.56 | -391.61 | -596.57 | -77.47 | -98.2 |
Long-Term Debt Issued | - | - | - | - | - | 45 |
Long-Term Debt Repaid | - | -10.54 | -7.83 | - | -45 | - |
Net Debt Issued (Repaid) | -10.54 | -10.54 | -7.83 | - | -45 | 45 |
Issuance of Common Stock | - | - | - | - | 1,056 | - |
Repurchase of Common Stock | -20.06 | -20.06 | - | - | - | - |
Common Dividends Paid | -19.3 | -29.16 | -40.6 | -60.91 | -0.26 | -3.03 |
Other Financing Activities | 19.82 | 7.75 | 9.99 | 6.75 | -23.46 | -5.47 |
Financing Cash Flow | -30.08 | -52.01 | -38.45 | -54.16 | 987.26 | 36.5 |
Foreign Exchange Rate Adjustments | -0.1 | 1.64 | 0.53 | 0.61 | -3.62 | -6.17 |
Net Cash Flow | 183.61 | -245.81 | -346.02 | -351.11 | 1,106 | 119.69 |
Free Cash Flow | -233.27 | -21.11 | -1.54 | 269.1 | 127.59 | 84.36 |
Free Cash Flow Growth | - | - | - | 110.91% | 51.25% | 8.80% |
Free Cash Flow Margin | -33.12% | -3.86% | -0.25% | 40.37% | 12.96% | 11.35% |
Free Cash Flow Per Share | -1.69 | -0.19 | -0.01 | 2.37 | 1.46 | 0.99 |
Cash Income Tax Paid | - | -6.77 | 9.01 | 14.07 | -35.75 | -14.41 |
Levered Free Cash Flow | -178.1 | -49.33 | -4.2 | 146.82 | 14.34 | 115.61 |
Unlevered Free Cash Flow | -177.47 | -48.85 | -3.57 | 147.98 | 15.35 | 116 |
Change in Working Capital | -1.74 | -1.74 | -45.71 | 132.21 | -57.36 | -19.84 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.